Acquisitions29 Sept 2025, 06:52 am
Lupin Ltd to Acquire VISUfarma B.V. for €190 Million from GHO Capital
AI Summary
Lupin Ltd, a global pharma major, announced its wholly owned subsidiary, Nanomi B.V., has signed a definitive agreement for the acquisition of VISUfarma B.V. from GHO Capital. The acquisition aligns with Lupin’s strategy to expand its European business and footprint and to advance the company’s global specialty franchise. VISUfarma's established commercial operations will provide market expansion opportunities and further business diversification across major European countries. The transaction is expected to be consummated by the end of 2025, subject to certain closing conditions.
Key Highlights
- Lupin Ltd to acquire VISUfarma B.V. for €190 million from GHO Capital.
- VISUfarma is a specialty pharmaceutical company focused on ophthalmology with a commercial presence in major European countries.
- The acquisition aligns with Lupin’s strategy to expand its European business and footprint and to advance the company’s global specialty franchise.
- VISUfarma's established commercial operations will provide market expansion opportunities and further business diversification across major European countries.
- The transaction is expected to be consummated by the end of 2025, subject to certain closing conditions.